National Medical Products Administration approves the listing of demcizumab injection.

Recently, the National Medical Products Administration approved the application by GlaxoSmithKline Trading Services Limited to market the injection of Demochi monoclonal antibodies. This product is used for the maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 and above. The listing of this product provides a new treatment option for relevant patients.